
More than 400 indirect deaths linked to LA wildfires, study suggests
The Palisades and Eaton fires tore through Los Angeles in January, destroying thousands of structures and leading to the evacuation of more than 100,000 Los Angeles residents.Why wildfires are becoming faster and more furiousThe far-reaching impacts of wildfire smoke – and how to protect yourselfThe latest study revealed that around 440 people are estimated to have died as a result of the wildfires between 5 January and 1 February. Researchers said they tallied the figure by looking at all deaths and their causes in Los Angeles during the period of the fires, and comparing it to similar data from previous years.The results show that there were nearly 7% more deaths during the wildfires. Some are attributed to lung and heart conditions exacerbated by smoke or stress, while others are more indirect - like delayed healthcare treatment for dialysis or cancer patients as a result of fire-related disruptions.The authors said that the findings underscore the need for officials to count both direct and indirect fatalities of wildfires and other climate-related emergencies when trying to quantify their impact. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies," the authors said, noting that their figures are provisional as there may have been additional fire-related deaths beyond the scope of the study.The BBC has reached out to Los Angeles County officials for comment on the study's findings.
Another study released on Wednesday in JAMA that looked at the aftermath of the 2023 Maui wildfires showed that 22% of adults in the region had reduced lung function, and half displayed symptoms of depression. The fires, which broke out in August 2023 and were the worst to affect Hawaii in recent history, killed at least 102 people and destroyed more than 2,000 structures. The authors of the Maui study said their results show the need for "sustained clinical monitoring and community-based mental health supports" months after a climate disaster.A second study on the Hawaii fires suggests that Maui saw the highest suicide and drug overdose rates in the month of the 2023 wildfires.Wildfires have become more frequent in recent years as a result of climate change, driven by hotter and drier weather that fuels fire spread.In addition to directly threatening lives and structures, smoke from wildfires has been shown to have adverse health effects on people.Wildfire smoke has been found to be harmful to certain immune cells in the lungs, with a toxicity four times greater than particulates from other types of pollution. This can have a long-term impact on cardiovascular health, experts have said.Older people, pregnant women and young children, as well as those with underlying health conditions, such as heart disease or asthma, are more likely to get sick, experts say. But the smoke can also impact healthy adults.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
20 minutes ago
- The Independent
Hundreds more may have died in LA's devastating fires in January than first reported, study finds
The death toll from the devastating early January wildfires around Los Angeles may be more than 400 people greater than the official tally, according to a new study. The paper, published by Finnish researchers in an American Medical Association journal, looked at the difference between expected and observed deaths in Los Angeles County as the fires were burning and found 440 excess deaths. They attribute the excess deaths to health conditions made worse by wildfire smoke, as well as mental health issues and health interrupted by the blazes, among other factors. 'The findings from this study underscore the need to complement direct fatalities estimates with alternative methods to quantify the additional mortality burden of wildfires and of climate-related emergencies more broadly,' the authors wrote. 'They also highlight the need for improved mortality surveillance during and after wildfire emergencies.' The study got the attention local leaders, who are still rebuilding after the Palisades and Eatons fires destroyed more than 16,000 structures and were attributed directly to 31 deaths. L.A. County Supervisor Kathryn Barger, whose district includes the hard-hit Altadena area, said she had seen the study's findings with interest. 'This study's assertion that over 400 excess deaths are a result of our Los Angeles wildfires is concerning,' she told the local Daily Breeze newspaper. 'In response, I've asked our county's Department of Public Health to thoroughly review the findings and provide their input. It is critical that we understand the full scope of the wildfires' impacts.' Another group of recent studies looked at similar indirect impacts from the 2023 Maui wildfire. The Maui fire was directly blamed for more than 100 deaths. But it also left 1 in 5 with lung damage and as many as half with symptoms of depression, one set of new research found. The month of the fire saw 13 suicide and overdose deaths, translating to nearly double the normal suicide and overdose death rates. Jonathan Purtle of New York University was the lead author of one study, which calculated rates of suicide and overdose deaths in Maui and Hawaii's four other counties. That research team found a 97% increase in suicides and overdose death rates on Maui during the month of the wildfires. The total number of suicide and overdose deaths was 13 that month — most of them suicides. They also found a 46% increase in such deaths in all five counties, which may have been influenced by displaced Maui residents migrating to other islands, the authors said. The increases did not last: Rates fells in the following months, the researchers found.


The Independent
an hour ago
- The Independent
Study reveals health risks of excessive screen time in teens
Excessive screen time in children and young adults significantly increases the risk of heart-related health conditions such as high blood pressure, high cholesterol, and insulin resistance. Danish researchers found that this link is particularly strong in individuals who experience reduced sleep, suggesting screen use may be displacing crucial sleep time. The study, involving over 1,000 Danish youths, revealed that each additional hour of screen time daily worsened cardiometabolic risk, with three extra hours leading to a notable increase. Machine learning identified a 'screen-time fingerprint' in blood samples, indicating biological changes that could signal long-term heart health risks from early screen habits. Experts recommend gradually reducing screen time, particularly by shifting screen use earlier in the day and prioritizing earlier and longer sleep, to mitigate these health risks.


The Guardian
an hour ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'